XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 Latest Research
  Risk Factors
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Infectious Diseases
 Respiratory Medicine
 Public Health
 Clinical Trials
 Medical News
 Awards & Prizes
 Special Topics
 Odd Medical News
 World News

Last Updated: Aug 19th, 2006 - 22:18:38

Pancreatic Cancer Channel
subscribe to Pancreatic Cancer newsletter

Latest Research : Cancer : Pancreatic Cancer

   DISCUSS   |   EMAIL   |   PRINT
Xeloda Dramatically Extends Survival Rates in Pancreatic Cancer
Nov 8, 2005, 15:28, Reviewed by: Dr.

"These data are very exciting and give new hope for pancreatic cancer sufferers who in general have a very short life expectancy."

- First Xeloda data to show survival benefit in this deadly cancer

The interim analysis of one of the largest phase III studies investigating the first-line treatment of advanced pancreatic cancer shows that adding Xeloda(R) (capecitabine) to standard chemotherapy (gemcitabine) significantly extends patient survival. The study showed that after a year, 1 patient out of 4 was still alive when treated with Xeloda plus standard chemotherapy compared to 1 in 5 taking standard chemotherapy alone. These remarkable findings were unveiled for the first time at the European Cancer Conference (ECCO) in Paris today.

"These data are very exciting and give new hope for pancreatic cancer sufferers who in general have a very short life expectancy," said Professor John Neoptolemos, Surgical Oncologist, Division of Surgery and Oncology, at the Royal Liverpool University Hospital. "Since the study began in May 2002, I have more patients who are still alive on the Xeloda combination after 12 months and longer - I have never seen so many patients achieve this before," he added.

Pancreatic cancer is one of the most aggressive forms of cancer and is the fifth leading cause of all cancer deaths in the developed world. Approximately 78,000 new cases of pancreatic cancer are diagnosed per year in Europe and 30,000 new cases in the US.(1) Very few treatment options exist.

Lead investigator, Professor David Cunningham said, "This is the first time that adding another cytotoxic drug to gemcitabine has improved the outcome for patients with inoperable pancreatic cancer and the trial results are therefore an important milestone. The combination of gemcitabine and capecitabine should now be considered one of the standard options for patients with advanced pancreatic cancer."

"The encouraging Xeloda data provide further survival benefit and quality of life for patients with this deadly disease and very limited treatment options. The latest results come on top of the recent positive recommendation by the FDA for Tarceva in pancreatic cancer. In addition, Roche has initiated studies with Avastin in this disease," commented William M. Burns, CEO Roche Pharma. "We have also filed Tarceva in pancreatic cancer in the European Union and other countries world-wide."

Notes to Editors:

This randomised study, funded and designed by Cancer Research UK, compared the survival of gemcitabine with gemcitabine plus Xeloda and involved 533 previously untreated patients with locally advanced or metastatic pancreatic cancer. Patients receiving the combination therapy lived significantly longer than those with standard therapy alone (median survival 7.4 vs. 6 months, HR= 0.80) with acceptable levels of toxicity. A higher percentage of patients were alive at 12 months in the group treated with Xeloda plus gemcitabine, compared to those treated with chemotherapy alone (26% v 19%).

About Xeloda

Xeloda is licensed in more than 90 countries worldwide including the EU, USA, Japan, Australia and Canada.

Roche received marketing authorisation for Xeloda as a first-line monotherapy (by itself) in the treatment of metastatic colorectal cancer (colorectal cancer that has spread to other parts of the body) in most countries (including the EU and USA) in 2001. Xeloda has also been approved by the European Medicines Agency (EMEA) and U.S. Food and Drug Administration (FDA) for adjuvant (post-surgery) treatment of colon cancer in March and June 2005, respectively.

Xeloda is licensed in combination with Taxotere(R) (docetaxel) in women with metastatic breast cancer (breast cancer that has spread to other parts of the body) and whose disease has progressed following intravenous (i.v.) chemotherapy with anthracyclines. Xeloda monotherapy is also indicated for treatment of patients with metastatic breast cancer that is resistant to other chemotherapy drugs such as paclitaxel and anthracyclines. Xeloda is licensed for the first-line treatment of stomach cancer that has spread, in South Korea.



Subscribe to Pancreatic Cancer Newsletter
E-mail Address:


About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of disease, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer and transplantation and a market leader in virology. In 2004 sales by the Pharmaceuticals Division totalled 21.7 billion Swiss francs, while the Diagnostics Division posted sales of 7.8 billion Swiss francs. Roche employs roughly 65,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai.

All trademarks used or mentioned in this release are legally protected.

Further Information Available (please contact Media Relations Contacts):

- Pancreatic Cancer Media Backgrounder
- Xeloda Fact sheet

Media Relations Contacts:
Julia Pipe
International Communications Manager
Tel: +41-79-263-9715

Donna Lindquist
Shire Health International, New York
Tel: +1-212-329-6254

Cancer Research UK Media Relations Contacts:
paul thorne
Tel: +44-(0)207-061-8300

Nick Stewart
Tel: +44-(0)207-061-8300


1. Ferlay J et al. GLOBOCAN 2002: Cancer Incidence, Mortality and
Prevalence Worldwide. IARC CancerBase No5, version 2.0, Lyon; IARC
Press 2004

Related Pancreatic Cancer News

Vitamin D May Cut Pancreatic Cancer Risk by Nearly Half
Post operative gemcitabine combination therapy improves survival in pancreatic cancer
Treatment of pancreatic carcinoma by adenoviral mediated gene transfer of vasostatin in mice
FDA Approves Tarceva for Advanced Pancreatic Cancer
Xeloda Dramatically Extends Survival Rates in Pancreatic Cancer
Red Meat Associated With Pancreatic Cancer Risk
3D MRI Useful in Detecting Most Lethal Cancers
New onset of hyperglycemic diabetes in adults age 50 or older - signal of underlying pancreatic cancer
Protein responsible for unchecked cell growth found
Disease progression model of pancreatic cancer developed

For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page


© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us